OS Therapies Inc
OS Therapies Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing immunotherapy and targeted cancer candidates. Its lead programs include OST-HER2 for osteosarcoma and OST-tADC, with development activities centered on preclinical work, clinical trials, and regulatory submissions.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueLead therapeutic candidate for osteosarcoma and other HER2-related oncology uses.
Next-generation targeted antibody-drug conjugate platform under development.
Early-stage research, assay work, and candidate modeling activities.
Subsidiary-related strategic alternatives and animal health activities.
Customers
OS Therapies does not sell commercial products in the traditional sense; its primary counterparties are regulators, clinical investigators, CROs, CDMOs, and research vendors that support development. If approved, its eventual customers would be hospitals, oncologists, and healthcare systems treating rare and HER2-expressing cancers. The company’s programs are aimed at patients with osteosarcoma and potentially other solid tumors.
FDA, MHRA, and EMA review clinical data and marketing applications for OST-HER2.
CROs, CDMOs, consultants, and labs provide trial execution, manufacturing, and testing.
Patients with recurrent osteosarcoma and other HER2-related solid tumors are the eventual end users.
Hospitals and oncologists would prescribe or administer the therapy if approved.
Academic and clinical partners may support biomarker analysis and future expansion studies.
Strategy
The company’s near-term strategy is to advance OST-HER2 through late-stage regulatory and pre-commercial milestones, using biomarker-supported clinical evidence to pursue conditional approvals. It is also extending its platform through OST-tADC modeling, while keeping optionality around its animal health subsidiary and other pipeline assets. Success depends on converting clinical data into regulatory filings and then broadening the program into additional HER2-related oncology settings.
Approval is the main value-creation event for a clinical-stage oncology company.
Clinical endpoint support is needed to strengthen the approval case.
Broader indications could increase the commercial value of the platform.
OST-tADC modeling may create a second development engine beyond OST-HER2.
Geography
OS Therapies is headquartered in the United States and conducts its development, regulatory, and corporate activities from there. Its lead program is being advanced through U.S., U.K., and European regulatory pathways, so its commercial opportunity is tied to multiple major healthcare markets. The company also references international regulatory and pre-commercial efforts as part of its development plan.
Risks
OS Therapies faces the classic risks of a development-stage biotech company: clinical failure, regulatory rejection, and long timelines before any product revenue. Its business also depends on third-party vendors and external financing, while equity overhang from warrants, options, and convertible securities can pressure the stock and complicate future capital raises.
- Regulatory approval riskImpact: CriticalLikelihood: Medium
OST-HER2 must satisfy agency standards for safety and efficacy before commercialization.
Exposure - Clinical development riskImpact: CriticalLikelihood: Medium
Phase IIb and biomarker data may not translate into approvable outcomes.
Exposure: OST-HER2 and future pipeline programs
- Financing and dilution riskImpact: HighLikelihood: High
The company has no product revenue and depends on external capital to fund operations.
Exposure - Dilution and trading pressure from securities overhangImpact: MediumLikelihood: High
Outstanding warrants, options, and preferred stock can increase share supply and affect valuation.
Exposure: Common stock
- Vendor and outsourcing execution riskImpact: MediumLikelihood: Low
Development work relies on CROs, CDMOs, labs, and consultants for trial and manufacturing tasks.
Exposure: Preclinical and clinical operations
Accounting
Judgemental itemsExternal trial, lab, and manufacturing costs are expensed as incurred and can swing with program activity.
Impact: Affects operating loss and comparability across quarters
Outstanding warrants may require fair value remeasurement depending on terms and classification.
Impact: Can create non-cash gains or losses
Employee and advisor awards are part of R&D and G&A costs.
Impact: Raises reported operating expenses without cash outflow
Convertible notes, preferred stock, and warrant exercises affect capital structure and EPS-like metrics.
Impact: Changes share count and balance sheet presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
PDS Biotechnology Corp
PDSB · Pharmaceutical Preparations
PDS Biotechnology Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing immunotherapy product candidates.
Aardvark Therapeutics, Inc.
AARD · Pharmaceutical Preparations
Terns Pharmaceuticals, Inc.
Pharmaceutical Preparations
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Seres Therapeutics, Inc.
MCRB · Pharmaceutical Preparations
Last updated: 24/09/2026